medigraphic.com
ISSN 2007-6800 (Print)

2020, Number S1

<< Back Next >>

Rev Mex Traspl 2020; 9 (S1)

Alterations of glucose metabolism in donor and recipient

Martínez-Juárez IA

Language: Spanish
References: 48
Page: 99-103
PDF size: 222.62 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Grams ME, Sang Y, Levey AS et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016; 374: 411-421.

  2. Spanish Society of Nephrology (SEN) and Spanish Transplant Organization (ONT). Recommendations for living-donor kidney transplantation. Nefrologia. 2010; 30: 1-105.

  3. Boudville N, Isbel N. The CARI guidelines. Donors at risk: impaired glucose tolerance. Nephrology (Carlton). 2010; 15 (Suppl 1): S133-S136.

  4. Andrews PA, Burnapp L, Manas D et al. Summary of the British Transplantation Society/Renal Association U.K. Guidelines for living donor kidney transplantation. Transplantation. 2012; 93: 666-673.

  5. Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011; 118: s209-s224.

  6. Morris RD, Rimm DL, Hartz AJ et al. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32 662 adult white women. Am J Epidemiol. 1989; 130: 112-122.

  7. Lentine KL, Kasiske BL, Levey AS et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101 (8S Suppl 1): S1-S109.

  8. Pascual J, Abramowicz D, Cochat P et al. European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia. 2014; 34: 293-301.

  9. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30: 753-759.

  10. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017; 75 (suppl 1): 4-12.

  11. Wareham NJ, Byrne CD, Williams R et al. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care. 1999; 22: 262-270.

  12. Vigneault CB, Asch WS, Dahl NK, Bia MJ. Should living kidney donor candidates with impaired fasting glucose donate? Clin J Am Soc Nephrol. 2011; 6 (8): 2054-2059.

  13. Okamoto M, Suzuki T, Fujiki M et al. The consequences for live kidney donors with preexisting glucose intolerance without diabetic complication: analysis at a single Japanese center. Transplantation. 2010; 89: 1391-1395.

  14. Shinzato T, Kurosawa A, Kubo T et al. No significant differences in short-term renal prognosis between living kidney donors with and without diabetes. Clin Exp Nephrol. 2018; 22 (3): 694-701.

  15. Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2008; 179 (3): 229-234.

  16. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26: 725-731.

  17. Lorenzo C, Hazuda HP, Haffner SM. Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab. 2012; 97 (3): 793-799.

  18. Lam NN, Lentine KL, Levey AS, Kasiske BL, Garg AX. Long-term medical risks to the living kidney donor. Nat Rev Nephrol. 2015; 11 (7): 411-419.

  19. Muzaale AD, Massie AB, Wang MC et al. Risk of end-stage renal dis- ease following live kidney donation. JAMA. 2014; 311: 579-586.

  20. Holscher CM, Bae S, Thomas AG et al. Early hypertension and diabetes after living kidney donation: a national cohort study. Transplantation. 2019; 103 (6): 1216-1223.

  21. Alegre-Díaz J, Herrington W, López-Cervantes M et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016; 375 (20): 1961-1971.

  22. Lopes GS, Lemos CC, Mandarim-De-Lacerda CA, Bregman R. Effect of unilateral nephrectomy on renal function of diabetic rats. Histol Histopathol. 2004; 19: 1085-1088.

  23. Garg AX, Muirhead N, Knoll G et al. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 2006; 70: 1801-1810.

  24. Iwai T, Miyazaki M, Yamada G et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study. Clin Exp Nephrol. 2018; 22 (2): 328-336.

  25. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017; 12 (12): 2032-2045.

  26. Sharif A, Hecking M, de Vries AP et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14 (9): 1992-2000.

  27. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344: 1608-1621.

  28. Papanas N, Liakopoulos V, Maltezos E, Stefanidis I. The diabetic foot in end stage renal disease. Ren Fail. 2007; 29 (5): 519-528.

  29. Ceresa CD, Aitken E, Dempster NJ, Kingsmore D. Outcomes of renal transplantation in patients with major lower limb amputation. Transplant Proc. 2014; 46 (1): 115-120.

  30. Aitken E, Ramjug S, Buist L, Kingsmore D. The prognostic significance of iliac vessel calcification in renal transplantation. Transplant Proc. 2012; 44 (10): 2925-2931.

  31. Baker RJ, Mark PB, Patel RK, Stevens KK, Palmer N. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol. 2017; 18 (1): 174.

  32. Zelle DM, Corpeleijn E, Deinum J et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care. 2013; 36: 1926-1932.

  33. Kervinen MH, Lehto S, Helve J, Grönhagen-Riska C, Finne P. Type 2 diabetic patients on renal replacement therapy: probability to receive renal transplantation and survival after transplantation. PLoS One. 2018; 13 (8): e0201478.

  34. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2011; 8 (1): 34-42.

  35. Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016; 37 (1): 37-61. doi: 10.1210/er.2015-1084.

  36. Cai R, Wu M, Lin M, Guo X, Xing Y. Pretransplant homeostasis model assessment of insulin resistance and fasting plasma glucose predict new-onset diabetes after renal transplant in chinese patients. Transplant Proc. 2019; 51 (3): 768-773.

  37. Morgan RD, O’Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012; 93 (12): 1179-1188.

  38. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008; 3 (3): 814-821.

  39. Cooper L, Oz N, Fishman G et al. New onset diabetes after kidney transplantation is associated with increased mortality-A retrospective cohort study. Diabetes Metab Res Rev. 2017; 33 (8). doi: 10.1002/dmrr.2920.

  40. Ghisdal L, Bouchta NB, Broeders N et al. Conversion from tacrolimus to cyclosporine A for new- onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant Int. 2008; 21: 146-151.

  41. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol. 2011; 22 (11): 2107-2718.

  42. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008; 19: 1411-1418.

  43. Kleinsteuber A, Halleck F, Khadzhynov D et al. Impact of pre-existing comorbidities on long-term outcomes in kidney transplant recipients. Transplant Proc. 2018; 50 (10): 3232-3241.

  44. Johal S, Jackson-Spence F, Gillott H et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabet Med. 2017; 34 (8): 1067-1073.

  45. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc. 2004; 36 (10): 2993-2996.

  46. Woodle ES, First MR, Pirsch J, Shihab F et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248 (4): 564-77. doi: 10.1097/SLA.0b013e318187d1da.

  47. Woodle E, Clark S, Stewart D et al. Fifteen year outcomes in the astellas double blind randomized controlled trial (RCT) comparing early corticosteroid withdrawal (CSWD) and long-term corticosteroid therapy continuation (CCS) in kidney transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3).

  48. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010; 90 (4): 343-349.




2020     |     www.medigraphic.com